Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not true. Period.
I don’t like the high volume in neg direction either. But I am hoping we hold 3 and rebound.
There’s no way reduce it could have leaked this early. I assume these drops are related to this ridiculous court case with all against amrn.
Thanks appreciate it !
Let’s see what happends
Appreciate your charts. I look at all aspects of amrn but mainly awaiting reduce it.
From charting, is ur theory broken with the 2 bearish days on high volume through the support or is there still a rebound in order.
If it’s not significant event then why is amrn trading over 2 mill shares (not typical of amrn ) and red. The street must think this is important ?
Personally I don’t think this suit matters much as long as aha adds Vascepa to the 2018 guidelines after a successful reduce it. However I must be wrong if the stock is held this low. It’s mind blowing.
BB. What ever happened to that suit against amrn you mentioned? It’s so long ago I never saw another post on it until you just mentioned it again here. Just curious.
Thanks.
Volume - what does it take for this stock to have heavy volume.
100 percent events any day
Already doing follow up visits
Ongoing lawsuit
Poster after poster demonstrating the blockbuster market for Vascepa.
Months away from read out of final results.
Thanks.
Have to say you were right on that and on stock price stuck below 450 without ITC investigation.
GOOD DD. Keep it coming. Big times ahead.
If 1612 by March 1st then if they find another event occurred in follow up in March, you think we can expect more than 1612 final events ?
So are we now guaranteed to not have trial end until at least 3/31 ?
True. The thing is we should see some price action next week. I can’t believe the street is that tuned in to all of these issues to not buy this stock. It has so much potential. At 3.70 we are essentially pricing in a failed trial. It’s getting ridiculous.
Agreed. Total BS. We need 100 percent events announced Tues am to get us back to focusing on positive reduce it results etc. This FDA screwing amrn can continue to a point but if we reduce death we have a golden ticket.
BB. I see your points. Just crazy what amrn has been through. You think anyone will bring this up at CC? I wonder what JT thinks about this.
BB-
It seems wrong that Hepaxa can sell as a medical food. How can FDA claim EE is a medical food when Vascepa is a drug. This just seems confusing with a lot of overlap.
I think everyone is shocked this stock doesn’t have a rocket behind it.
Time will fell with conf call next week and results soon.
I bought more.
I couldn’t be more bullish on the science behind amrn. Might be the best drug with the most potential I’ve witnessed in as long as I can remember.
You think we will hit 100 percent events by March 1 st or are we going to be under
Interesting.
Currently we use New Orleans Head CT or Canadian CT Head rules (see website md calc online) which approach 100 % sensitivity of who needs to get a CTH and who you can just discharge. Not sure how much we need a blood test to be better than that but sure can aid in the decision making process in certain cases.
Thank you HDG. I almost left the board out of frustration until I got some comical relief from your post. lol
We are talking about medicines to get to 15 % RRR not the obvious therapies that all physicians recommend and many patients don’t do ( quit smoking eat healthy etc). Obviously Kaiser health is diff and will have a more compliant patient population but no physician would withhold that therapy on someone. That would be absolutely ridiculous.
Having a drug with a 15 % RRR and possibly death as an end point is nothing to overlook. Your post just really fails to understand how deep this drug would penetrate the health care system.
Kiwi - that is completely ridiculous. To think 15 percent RRR is meaningless. Come on. I hope you don’t really think that. Completely flawed logic.
The nice part about the AHA is they get the diff between the different contents of the drugs.
I truly see AHA favorably including high dose EPA such as Vascepa in the guidelines for multiple indications.
This would be absolutely blockbuster.
They are following this reduce it trial (and strength ) but they will update their guidelines after the reduce it trial.
I know what you mean regarding the ratios However, Research always has its limitations. This is not a BS study in any way. A well done meta analysis with as large a number of pts as you will ever have looking into this issue. Published in JAMA. Major journal with physicians in all specialities reading it.
Bottom line low dose supplements mainly containing epa and dha in some mixture are ineffective (yes helps included too but the other trials were epa/dha)
This is big news for amrn and mainly to help guide the AHA in their upcoming recommendations as long as reduce it is successful.
Amrn can take over the market with a positive reduce it study.
Landmark article published. I just got the full pdf. Nice read.
I believe AHA will add Vascepa to the guidelines after reduce it. Game changer. Supplements don’t do it.
IMPORTANCE Current guidelines advocate the use of marine-derived omega-3 fatty acids supplements for the prevention of coronary heart disease and major vascular events in people with prior coronary heart disease, but large trials of omega-3 fatty acids have produced conflicting results.
OBJECTIVE Toconductameta-analysisofalllargetrialsassessingtheassociationsofomega-3 fatty acid supplements with the risk of fatal and nonfatal coronary heart disease and major vascular events in the full study population and prespecified subgroups.
DATASOURCESANDSTUDYSELECTION Thismeta-analysisincludedrandomizedtrialsthat involved at least 500 participants and a treatment duration of at least 1 year and that assessed associations of omega-3 fatty acids with the risk of vascular events.
DATAEXTRACTIONANDSYNTHESIS Aggregatedstudy-leveldatawereobtainedfrom10large randomized clinical trials. Rate ratios for each trial were synthesized using observed minus expected statistics and variances. Summary rate ratios were estimated by a fixed-effects meta-analysis using 95% confidence intervals for major diseases and 99% confidence intervals for all subgroups.
MAINOUTCOMESANDMEASURES Themainoutcomesincludedfatalcoronaryheartdisease, nonfatal myocardial infarction, stroke, major vascular events, and all-cause mortality, as well as major vascular events in study population subgroups.
RESULTS Ofthe77917high-riskindividualsparticipatinginthe10trials,47803(61.4%)were men, and the mean age at entry was 64.0 years; the trials lasted a mean of 4.4 years. The associations of treatment with outcomes were assessed on 6273 coronary heart disease events (2695 coronary heart disease deaths and 2276 nonfatal myocardial infarctions) and
12 001 major vascular events. Randomization to omega-3 fatty acid supplementation (eicosapentaenoic acid dose range, 226-1800 mg/d) had no significant associations with coronary heart disease death (rate ratio [RR], 0.93; 99% CI, 0.83-1.03; P = .05), nonfatal myocardial infarction (RR, 0.97; 99% CI, 0.87-1.08; P = .43) or any coronary heart disease events (RR, 0.96; 95% CI, 0.90-1.01; P = .12). Neither did randomization to omega-3 fatty acid supplementation have any significant associations with major vascular events (RR, 0.97; 95% CI, 0.93-1.01; P = .10), overall or in any subgroups, including subgroups composed of persons with prior coronary heart disease, diabetes, lipid levels greater than a given cutoff level, or statin use.
CONCLUSIONSANDRELEVANCE Thismeta-analysisdemonstratedthatomega-3fattyacids had no significant association with fatal or nonfatal coronary heart disease or any major vascular events. It provides no support for current recommendations for the use of such supplements in people with a history of coronary heart disease.
Just doesn’t make sense to me how they can see amrn doing the same thing as them and not file patents in the mean time or protect themselves. Billions and BILLIOns lost on their part.
Are you surprised as to why they wouldn’t pursue the US for approval or at least patent protect here in the past? Obviously now it’s too late.
Likely will be small number of composite mace on both sides anyway but still very weak. I didn’t see that in study design previously. Thanks for pointing that out.
BB- Why again was Vascepa not infringing on epadel patents etc if so similar? I know this has been a topic a long time ago but just curious.
Idk where you guys got this from. Silent MI is not going to be diagnosed on EKG and added to MACE events. That would be terribly distorting the numbers.
Silent MI can only be surmised based on q waves on EKG. However not everyone wth q waves on EKG suffered a silent MI. There’s ambiguity and it’s not a hard endpoint a trial would be interested in following.
That would be really nice to have the accelerated approval that quick. I think it can happen given how important Vascepa is.
This ITC thing is still hanging over the stock. I hope the court doesn’t uphold the ITC decision. We need to catch a break.
BB- Redacted version is within a few days depending on local rules as my previous post states. Stay tuned.
BB- My friend is an attorney. Follows the board daily and can’t post because it says he is jail bird ? We aren’t sure what that means but it wont let him post.
Anyway he said to say “BB. Im a fellow follower of this board and long amrn investor. Great work generally. I follow amrn legal details closely. Typically a redacted version will be filed within a few days ( it depends on local rules) we can speculate as to why it was sealed. Likely the inclusion of proprietary information in the brief that the ITC completely disregarded by failing to investigate. Hope this helps “.
Anyone know how quickly the committee finds out about events? In other words if the last event let’s say a MI happened today, could the committee know in the next few days and report to amrn that the last event occurred ?
I am not sure how quickly reporting happends. Any phds out there that routinely conduct research ?
Pyrr- everything in medicine has 2 sides. You can always find studies to the negative. For instance for stroke there’s more studies that tpa (clot buster ) doesn’t work then it does work (crazy right) but it’s standard of care to give it. quality of studies matter. Number of pts and other factors etc.
From what I read in that study posted, that is a garbage argument about TG.
Pyr- That study is completely flawed. Small study. Retrospective. Ton of confounders. Two groups studied were not equal. Some confidence intervals almost reach 1 barely significant. And as B.B. pointed out this was from over 8 years ago and these pts were not treated with Vascepa.
You can toss that study and move on.
Guys. The theory about the flu shot helping placebo needs to stop. It is 100 percent false.
This year the flu shot is almost worthless and has little protection at all even if you got the vaccine. I’ve seen a ton of flu in those with the vaccine his year in particular but every year as well.
Anyone know when amrn becomes unblinded ?
Is it when the last event occurs and trial ends (any day ) or is it not until after all data gathered in the follow up visits in March.
Pyrr- You have no basis for believing this won’t have a positive result.
This is one of the few if any biotech’s that we have great insight into why this will succeed as there is ample lot to support a very likely positive reduce it trial. Couldn’t be more bullish.
As a doc on this board I can’t say it’s 100 percent bc nothing in medicine. Is. However, it is as close as a lock that this will break 450 regardless of ITC action. See any of my prior posts as to why this doesn’t rely on ITC. That’s background noise. A strong reduce it and aha guidelines is putting this in and it’s going to be standard of care plus extrapolated and given to other pts off label as is with aspirin. Multi Billion dollar potential.
Gluck
Disclosure
-In heavy, long amrn.
Few posts as per could be- this ones for you ha.
Good things ahead for 2018.
Price action wise this is the best amrn has acted in years. Building a higher support. Holding gains.
450-5 bucks shouldn’t be too long away.
Hold on tight.
Happy new year all.
I suspect we touch upon 440-450 on this run. Time will tell.
Lot of catalysts with Q1 days away (trial can end at any moment).
Jan conf call.
Court can send investigation back to ITC possibly in Jan- will see.
Bears OWN amrn but they owned it based on time. Now times running out.